Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kuramochi, Hidekazu ^a   Nakajima, Go ^a   Kaneko, Yuka ^a   Nakamura, Ayako ^a   Inoue, Yuji ^a   Yamamoto, Masakazu ^a   Hayashi, Kazuhiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROPYRIMIDINE; MESSENGER RNA; AMPHIREGULIN; EPIDERMAL GROWTH FACTOR; EPIREGULIN; GLYCOPROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; AMPHIREGULIN GENE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; EPIREGULIN GENE; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT DURATION; TUMOR GENE; WILD TYPE; COLORECTAL TUMOR; GENETICS; LIVER TUMOR; METASTASIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EPIDERMAL GROWTH FACTOR; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857965566     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-88     Document Type: Article

References (21)

1. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990, 265(14):7709-7712.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345. 10.1056/NEJMoa033025, 15269313.
3. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-1664. 10.1200/JCO.2006.08.1620, 17470858.
4. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22(7):1201-1208. 10.1200/JCO.2004.10.182, 14993230.
5. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671. 10.1200/JCO.2008.20.8397, 19114683.
6. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-379. 10.1200/JCO.2007.12.5906, 18202412.
7. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28(31):4697-4705. 10.1200/JCO.2009.27.4860, 20921465.
8. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27(12):2091-2096. 10.1200/JCO.2009.21.9170, 19188670.
9. Inatomi O, Andoh A, Yagi Y, Bamba S, Tsujikawa T, Fujiyama Y. Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med 2006, 18(3):497-503.
10. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25(22):3230-3237. 10.1200/JCO.2006.10.5437, 17664471.
11. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009, 27(30):5068-5074. 10.1200/JCO.2008.21.3744, 19738126.
12. Yamada M, Ichikawa Y, Yamagishi S, Momiyama N, Ota M, Fujii S, Tanaka K, Togo S, Ohki S, Shimada H. Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res 2008, 14(8):2351-2356. 10.1158/1078-0432.CCR-07-4499, 18413824.
13. Watanabe T, Kobunai T, Yamamoto Y, Kanazawa T, Konishi T, Tanaka T, Matsuda K, Ishihara S, Nozawa K, Eshima K, et al. Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. Eur J Cancer 2010, 46(11):2119-2126. 10.1016/j.ejca.2010.04.019, 20570135.
14. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 2006, 12(1):29-33. 10.1158/1078-0432.CCR-05-1275, 16397020.
15. Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M, Danenberg KD, Danenberg PV. Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. Cancer Chemother Pharmacol 2010, 65(5):825-831. 10.1007/s00280-009-1087-5, 19701635.
16. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV. 5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer 2006, 119(3):522-526. 10.1002/ijc.21692, 16572420.
17. Oliveras-Ferraros C, Vall-Llovera AM, Salip DC, Vazquez-Martin A, Cufi S, Queralt B, Martin-Castillo B, Brunet J, de Llorens R, Menendez JA. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Invest New Drugs 2012, 30(2):846-852. 10.1007/s10637-010-9612-2, 21161326.
18. Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, Rowinsky EK, Xu LA, Harbison CT, Clark EA, et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2010, 104(3):488-495.
19. Jonker DJK, Harbison C. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A Phase III trial of cetuximab versus best supportive care (BSC). ASCO Annual Meeting 2009,
20. Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, Wistuba II, Kurie JM. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila) 2008, 1(3):201-207.
21. Shigeishi H, Higashikawa K, Hiraoka M, Fujimoto S, Mitani Y, Ohta K, Takechi M, Kamata N. Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas. Oncol Rep 2008, 19(6):1557-1564.